Product logins

Find logins to all Clarivate products below.


Osteoarthritic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Osteoarthritic Pain (US)

Osteoarthritic (OA) pain affects more than 30 million people in the United States, and the aging population and rising obesity rates are expected to drive further increases. Current treatments, including intra-articular agents, NSAIDs, antidepressants, opioids, and AEDs, are prescribed to alleviate the pain and enhance mobility, but more-effective, well-tolerated alternatives are needed. In this crowded and largely generic market, a deep understanding of treatment patterns is essential for the successful introduction of a novel analgesic.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed OA pain patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed OA pain patients?
  • How has Zilretta been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of OA pain patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of OA pain patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key companies: Pacira Biosciences, Collegium Pharmaceuticals, Protega Pharmaceuticals, Averitas Pharma, Kowa

Key drugs: Zilretta, NSAIDs, gabapentin, intra-articular corticosteroids, celecoxib, Xtampza ER, Qutenza, Nucynta, tramadol

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Related Market Assessment Reports

Report
Dry and Wet Age-Related Macular Degeneration – Landscape & Forecast – Disease Landscape & Forecast (G7)
Age-related macular degeneration (AMD) is a late-onset retinal disease that diminishes central visual acuity due to photoreceptor degeneration in the macula, leading to vision impairment and…
Report
Heart Failure – Landscape & Forecast – Disease Landscape & Forecast (G7)
Heart failure (HF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. Acute heart failure (AHF) and…
Report
Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by…
Report
Emerging Vaccines – Landscape & Forecast – Disease Landscape & Forecast (G7)
Vaccination programs have had a revolutionary impact on global public health, not only dramatically reducing the incidence of infectious disease but also reducing childhood and adult mortality and…
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the…